Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma

Local tumour control and radiation side effects for fractionated stereotactic photon beam radiotherapy compared to proton beam radiotherapy in uveal melanoma

•Uveal melanoma treated with stereotactic radiotherapy: 5-year tumour control 96.1%.•Uveal melanoma treated with proton beam radiotherapy: 5-year tumour control 96.1%.•Vitreous haemorrhages occur more after stereotactic radiotherapy than proton beam.•Larger tumours are a risk for maculopathy and enu...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology Vol. 157; pp. 219 - 224
Main Authors: van Beek, Jackelien G.M., Ramdas, Wishal D., Angi, Martina, van Rij, Caroline M., Naus, Nicole C., Kacperek, Andrzej, Errington, Roger D., Damato, Bertil, Heimann, Heinrich, Kiliç, Emine
Format: Journal Article
Language:English
Published: Ireland Elsevier B.V 01-04-2021
Subjects:
Eye Enucleation
Fractionated stereotactic photon beam radiotherapy
Humans
Local tumour control
Melanoma - radiotherapy
Neoplasm Recurrence, Local
Netherlands
Proton beam radiotherapy
Protons
Radiosurgery
Retrospective Studies
Side effects
United Kingdom
Uveal melanoma
Uveal Neoplasms - radiotherapy
United Kingdom
Netherlands
Uveal melanoma
Side effects
Proton beam radiotherapy
Fractionated stereotactic photon beam radiotherapy
Local tumour control
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Uveal melanoma treated with stereotactic radiotherapy: 5-year tumour control 96.1%.•Uveal melanoma treated with proton beam radiotherapy: 5-year tumour control 96.1%.•Vitreous haemorrhages occur more after stereotactic radiotherapy than proton beam.•Larger tumours are a risk for maculopathy and enucleation. To compare the adverse side effects of fractionated stereotactic photon beam radiotherapy (fSRT) with proton beam radiotherapy (PBR) in patients with uveal melanoma (UM). A retrospective study investigating 306 UM patients treated with fSRT (N=153) by the Rotterdam Ocular Melanoma Study group (ROMS), The Netherlands, between 1999–2014 or with PBR (N=153) at the Royal Liverpool University Hospital and the Clatterbridge Cancer Centre, Bebington, United Kingdom, between 1993–2014. The tumours treated with fSRT were matched with tumours treated with PBR based on sex, left or right eye, TNM classification, posterior margin ≤ or > 3mm of the fovea and of the optic disc. The five-year actuarial rates of tumour recurrence were 4.5% for fSRT and 6.1% for PBR. For fSRT and PBR, the five-year actuarial rates of maculopathy were 14.9% and 12.4%, and for vitreous haemorrhage were 29.4% and 4.7%, respectively. Only vitreous haemorrhage (HR: 0.19, 95% CI: 0.07–0.56) was more common after fSRT compared to PBR. Overall, larger tumours were risk factors for maculopathy and secondary enucleation. Both treatments have excellent local tumour control. In matched groups, vitreous haemorrhage was the only adverse side effect showing a significant difference between groups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.01.030